Investors focused on the Medical space have likely heard of DaVita (DVA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
DaVita is a member of our Medical group, which includes 931 different companies and currently sits at #14 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. DVA is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for DVA's full-year earnings has moved 12.56% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, DVA has moved about 19.43% on a year-to-date basis. At the same time, Medical stocks have lost an average of 1.32%. This means that DaVita is outperforming the sector as a whole this year.
Looking more specifically, DVA belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #100 in the Zacks Industry Rank. This group has gained an average of 8.66% so far this year, so DVA is performing better in this area.
Investors with an interest in Medical stocks should continue to track DVA. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of DaVita (DVA - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
DaVita is a member of our Medical group, which includes 931 different companies and currently sits at #14 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. DVA is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for DVA's full-year earnings has moved 12.56% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
According to our latest data, DVA has moved about 19.43% on a year-to-date basis. At the same time, Medical stocks have lost an average of 1.32%. This means that DaVita is outperforming the sector as a whole this year.
Looking more specifically, DVA belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #100 in the Zacks Industry Rank. This group has gained an average of 8.66% so far this year, so DVA is performing better in this area.
Investors with an interest in Medical stocks should continue to track DVA. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on DVA - FREE